Sodium polystyrene sulfonate was applied to twenty-two cases with hyperkalemia and the following conclusions have been obtained. 1) The agent is clinically safe and effective for hyperkalemia. 2) Clinical value of the drug is more than that expressed by the serum potassium levels, because of its dramatic effect on the patient's poor prognosis. 3) Its effect was observed even in fasting patients, on low-potassium and/or on low-salt diet. 4) As to side effects, nothing worthy to mention was observed. Possibility of hypernatremia, hypocalcemia and hypokalemia must be considered as to dosage, duration, method of administration, diet and combined medications. Our attention must be paid especially on hypopotassemia whenever patient is on digitalisation or in the diuretic phase. 5) Use of this agent with dialysis should become an indispensable part in the management of acute renal failure.
展开▼
